Patient Adherence: The Next Frontier in Patient Care - Key findings from Capgemini’s latest Vision & Reality research
•Download as PPTX, PDF•
3 likes•1,952 views
Lack of patient adherence to prescribed medications poses a tremendous challenge to the global healthcare community. Bridging the adherence gap is a ‘must do’ for pharmaceutical companies to protect their top line while transforming themselves from product to patient-centric organizations. This is the result of a Capgemini Consulting research across Europe and the United States. The aim of the research was to understand the root causes of non-adherence, how the industry has addressed non-adherence in the past and what an innovative approach should look like. http://www.capgemini.com/services-and-solutions/by-industry/life-sciences/vision-and-reality/
![Vision & Reality is Capgemini Consulting’s 9th annual thought leadership publication for the Life Sciences industry Each year Capgemini Consulting examines a topic critical to the life sciences industry… This year we have focused on the issue of patients’ adherence to medication ,[object Object],Sector Representation ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Recommended
More Related Content
Viewers also liked
Viewers also liked (12)
More from Capgemini
More from Capgemini (20)
Recently uploaded
Recently uploaded (20)
Patient Adherence: The Next Frontier in Patient Care - Key findings from Capgemini’s latest Vision & Reality research
- 1. Vision & Reality 9th EditionPatient Adherence: The Next Frontier in Patient CareMay 2011
- 3. Payers: 7
- 6. Europe: 18
- 7. Including: France, Denmark, Germany, Netherlands, Portugal, UK, Spain and Switzerland.
- 8. Additionally, secondary research was conducted by Capgemini’s Life Sciences Strategy LabNote: (1) Others include Patient Advocacy Groups, Academic centres and a healthcare consulting group Copyright © 2011 Capgemini Consulting. All rights reserved. 2
- 10. Extent to which a patient follows a prescribed treatment plan agreed on with the physician
- 12. 9 Only about 50% of patients take medications as prescribed and there is a sharp drop in adherence over time on treatment Adherence rates across the duration of therapy Adherence rates of select conditions in US, 20081 Adherence rates to prescribed medicines estimated by respondents2 Source: (1) Andree Bates, “Ensuring Profitable Patient Adherence Programs”, Eularis, March 2010 (2) Source: Capgemini external interviews - Q2) What in your opinion is the current level of adherence in patients? Copyright © 2011 Capgemini Consulting. All rights reserved. 4
- 13. We analyzed factors of non-adherence, influencers of patient behaviors, and interventions to improve adherence Dimensions of Patient Adherence Source: Capgemini analysis Copyright © 2011 Capgemini Consulting. All rights reserved. 5
- 14. Across all respondent groups, patient attitude and therapy complexity were identified as main factors of non-adherence Average rating of factors driving adherence across respondent groups Q4) Could you please prioritize the most dominant factors and also identify the top 3 stakeholders who can influence these factors? Source: Capgemini external interviews Copyright © 2011 Capgemini Consulting. All rights reserved. 6
- 15. But things are changing and focus on patient adherence improvement will increase Healthcare Reforms Healthcare Industry Involvement and Collaboration Levers to Improve Adherence Digital Health Media Technology Advancements Copyright © 2011 Capgemini Consulting. All rights reserved. 7
- 16. Going forward, we recommend companies adopt a comprehensive and coherent framework to address patient adherence Source: Capgemini analysis Copyright © 2011 Capgemini Consulting. All rights reserved. 8
Editor's Notes
- First of all, it is important to agree on the meaning of the word “adherence”. Patient adherence is most commonly defined as compliance (that is to say taking a treatment as prescribed) and persistence (that is to say consistently taking a treatment over a period of time). It also implies an increased role of the patient in his own treatment.This is the definition that we will use across our study.
- Adherence rates across most therapeutic areas are very low – only about 50% of patients take medications as prescribed. Our survey shows that patients drop off at different points of time on treatment. About a third of patients don’t even fill the prescription in the first place. When they do fill it, they tend to stop refilling after a few months. Therefore after 6 months, only about 43% of people continue to refill their prescriptions.
- In order to understand the current industry state for patient adherence, we analyzed 3 areas:First, we tried to understand the reasons why patients don’t adhere to treatment. We found that these reasons are related to the patient and his behavior, but also to the characteristics of the disease, the treatment and the access to treatment in the healthcare system.Then we looked at influencers of patient behavior, and we found that adherence is not a top priority for most stakeholders - for example, physicians are a major influencer but seldom have time to educate patients on the importance of adherence.Finally, we looked at existing initiatives to improve adherence. We found that most of them had limited impact on patient behaviors, because they were isolated tactics that lacked consistency and failed to efficiently address patient needs.
- As an example illustrating our findings, let’s look at the factors for non-adherence.Most interviewees agree that non-adherence is mainly due to the patients’ lack of understanding of disease and treatment, which causes them to have a wrong attitude. Patients are not aware of the importance of adherence and are forgetful. As a result, they abandon treatment if they don’t see improvement, or on the contrary if they feel better.The second most important set of factors is related to the treatment itself: patients drop off because of side-effects or because the administration of drug is too cumbersome for their lifestyle.For more details on our findings, please refer to our report.
- Looking at the current state, we have seen that adherence improvement has not been a priority for the industry. However looking forward, we expect many things to change: we have seen 4 levers that will likely increase focus on patient adherence improvement.The first lever is related to the involvement of different stakeholders. Their roles will change: for example, payers are likely to get involved, linking adherence to reimbursement levels. Besides, our interviewees expect more collaboration between providers, pharma, payers and patients.The second lever is related to healthcare reforms. For example, reforms on payment in the US shift from fee-for-service to outcome-based incentives and will encourage providers to work towards improved patient adherence.The third lever is the digital health media such as specialized online forums and patient communities. These media will enable all stakeholders to better keep in touch with patients, with better chances of influencing their behavior.The fourth and last lever we identified is related to different technology advancements, that offer additional adherence improvement tools - such as smart packaging or remote patient monitoring.
- However, beyond isolated tactics, pharmas need a more consistent approach to patient adherence in order to maximize their impact by creating a entirely new patient experience.First of all, they need to make adherence a key pillar of marketing and sales efforts. Adherence should be taken into account early in development to influence product features. All patient leakages should be reviewed thoroughly to identify opportunities. The analysis should be comprehensive, and go beyond the levers that pharma can utilize directly, to include relevant influence points from all healthcare stakeholders. The impact of all patient touch points must be maximized in an economical way: this will require companies to understand which patients represent the highest value for their adherence programs.Finally Pharma has to make sure that it is enriching the quality of life of the patients while gathering continuous feedback from them to improve its efforts. We explore each step of this framework in more detail in our report.